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Abstract
Background: Sequence variants in genes functioning in folate-mediated one-carbon metabolism are hypothesized
to lead to changes in levels of homocysteine and DNA methylation, which, in turn, are associated with risk of
cardiovascular disease.
Methods: 330 SNPs in 52 genes were studied in relation to plasma homocysteine and global genomic DNA
methylation. SNPs were selected based on functional effects and gene coverage, and assays were completed on
the Illumina Goldengate platform. Age-, smoking-, and nutrient-adjusted genotype–phenotype associations were
estimated in regression models.
Results: Using a nominal P ≤ 0.005 threshold for statistical significance, 20 SNPs were associated with plasma
homocysteine, 8 with Alu methylation, and 1 with LINE-1 methylation. Using a more stringent false discovery rate
threshold, SNPs in FTCD, SLC19A1, and SLC19A3 genes remained associated with plasma homocysteine. Gene by
vitamin B-6 interactions were identified for both Alu and LINE-1 methylation, and epistatic interactions with the
MTHFR rs1801133 SNP were identified for the plasma homocysteine phenotype. Pleiotropy involving the MTHFD1L
and SARDH genes for both plasma homocysteine and Alu methylation phenotypes was identified.
Conclusions: No single gene was associated with all three phenotypes, and the set of the most statistically
significant SNPs predictive of homocysteine or Alu or LINE-1 methylation was unique to each phenotype. Genetic
variation in folate-mediated one-carbon metabolism, other than the well-known effects of the MTHFR c.665C>T
(known as c.677 C>T, rs1801133, p.Ala222Val), is predictive of cardiovascular disease biomarkers.
Background
Folate and other B vitamins play key roles in biologic
processes important to health, including DNA synthesis
and the generation of cellular methylation potential.
Folate status is influenced by both dietary intake and
variation in genes encoding folate-related enzymes, and
altered folate status due to nutritional or genetic pertur-
bations is associated with adverse outcomes, including
birth defects, cardiovascular disease (CVD), and cancer
[1].
Elevated plasma homocysteine, a sulfur-containing
amino acid by-product of folate metabolism, is a marker
of disturbed folate-mediated one-carbon metabolism,
and is associated with an increased risk of CVD [2-5].
Homocysteine levels are modulated by nutrition, parti-
cularly folate and vitamin B-12 [6], and by genetic var-
iants, including a well-studied SNP in the
methylenetetrahydrofolate reductase gene MTHFR
c.665C>T (known as c.677 C>T, rs1801133, p.Ala222-
Val)[7].
The association of homocysteine with CVD is
hypothesized to be mediated, in part, by changes in
DNA methylation [8]. Folate-mediated one-carbon
metabolism is linked to DNA methylation status
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sal methyl donor, and through the activity of enzymes
involved in methylation reactions [9,10].
LINE-1 and Alu elements are abundant, transposable
elements whose methylation status has been shown to
be highly correlated with genome-wide DNA methyla-
tion in some studies [11,12]. Atherosclerosis is charac-
terized by global DNA hypomethylation and
transposable element methylation levels are associated
with heart disease, stroke, and total mortality; reduced
LINE-1 methylation was associated with an increased
incidence of ischemic heart disease and stroke in the
Normative Aging Study (NAS) [13]. These findings con-
tribute to interest in global genomic DNA methylation
as a potential biomarker of CVD risk.
Most previous work investigating variation in genes
contributing to folate-mediated one-carbon metabolism
in relation to homocysteine and genomic methylation
phenotypes focused on a small number of candidate
genes; however, other enzymes and genes may also be
important; thus this study represents both first report
and replication efforts. To investigate the genetic and
nutritional predictors of homocysteine and methylation
phenotypes, this candidate gene study examined varia-
tion across the network of genes representing folate-
mediated one-carbon metabolism in relation to homo-
cysteine and methylation outcomes. 330 single nucleo-
tide polymorphisms (SNPs) in 52 genes with a role in
folate-mediated one-carbon metabolism were studied.
T h es e to fg e n e s ,t h eS N Pm a r k e r s ,a n dt h en u t r i e n t s
examined in this study were selected to represent the
full functional variation of the folate-mediated one car-
bon metabolic pathway.
Methods
Study population
The Veterans’ Administration (VA) established the NAS
in 1961. 2,280 men aged 21-81 years (mean age of 42 y
at study entry) were enrolled in the study on the basis
of health criteria; details have been described elsewhere
[14,15]. The analyses described herein focus on non-
Hispanic white males using data from the subset of men
(~ 700) with measurements of homocysteine and global
genomic DNA methylation (Alu and LINE-1). This
study complied with the Helsinki Declaration and was
approved by the following: Brigham and Women’s Hos-
pital Human Subjects committee, VA R&D committee,
Harvard School of Public Health, Cornell University
Committee on Human Subjects.
DNA extraction, SNP selection and genotyping
Genomic DNA was extracted from stored frozen buffy
coat of 7 ml whole blood using the QIAamp DNA
Blood Kit (QIAGEN, Valencia, CA). The REPLI-g whole
genome amplification kit (QIAGEN) was used to amplify
genomic DNA when quantity was insufficient for
genotyping.
52 genes that contribute to folate-mediated one-car-
bon metabolism were identified (Additional file 1). SNP
selection encompassed 2 kb on either side of the gene
to include promoter and/or regulatory region variants; a
total of 384 SNPs were selected. 384 SNPs were sub-
mitted to the Center for Inherited Disease Research at
the Johns Hopkins University for genotyping via an Illu-
mina GoldenGate custom genotyping panel. Genotype
f r e q u e n c i e si nc o n t r o l sw e r ec o m p a r e dw i t ht h o s e
expected in Hardy-Weinberg equilibrium (HWE). Of the
384 SNPs originally submitted, 54 were ultimately
excluded, leaving 330 SNPs available for analysis (Addi-
tional file 2).
Extensive previously collected data on study partici-
pants includes physical measurements, lifestyle factors,
and blood assays. Plasma folate, vitamin B-6 (as pyri-
doxal-5’-phosphate; PLP) and vitamin B-12 were assayed
as previously described [16]. Plasma total homocysteine
was assayed in the same unselected subset of stored
blood samples as plasma folate, vitamin B-6, and vita-
min B-12 [16]. The analysis of transposon DNA methy-
lation was reported in prior publications [17,18].
Restricted maximum likelihood and ordinary least
squares regression models evaluated the relation
between SNPs and the plasma homocysteine and global
DNA methylation phenotypes; maximum likelihood
regression was used to evaluate epistatic interactions
with the dummy-coded MTHFR SNP. Previous work in
this cohort demonstrated no population substructure
[19], thus no adjustments were made. All regression
models were adjusted for age, smoking status, and nutri-
ent residuals (variation in nutrient not predicted by
SNP), and an extended model also adjusted for the
MTHFR rs1801133 variant (coded as recessive to
account for the pattern of association using the fewest
model terms). For the homocysteine phenotype, further
models tested the interaction of each genotype with the
rs1801133 SNP. For all phenotypes, further models
tested the interaction of each genotype with the
nutrients.
For main effects, regression coefficients with a nom-
inal P ≤ 0.005 were reported, and a False Discovery Rate
(FDR) multiple testing correction [20] was applied, with
an FDR-adjusted P value significance threshold of 0.05;
final models were conditional on a first step that
selected the best genetic model for each SNP, thus the
FDR is conditional on this first step. For interactions, a
less stringent FDR-adjusted P value significance thresh-
old of 0.20 was used. For gene-nutrient interactions,
regression coefficients with a nominal P ≤ 0.02 were
reported, given few results reached the FDR threshold.
Wernimont et al. BMC Medical Genetics 2011, 12:150
http://www.biomedcentral.com/1471-2350/12/150
Page 2 of 10To assess effect modification, product terms between
the SNP and the nutrient biomarker residual were
included in models. Interactions were captured in a sin-
gle model term; significance of the interaction was
assessed by the P value for the interaction term. Interac-
tions with MTHFR rs1801133, which was dummy-
coded, were assessed with the likelihood ratio test
(LRT). All statistical analyses were conducted with SAS
v. 9.2 (SAS, Cary, NC).
Additional details on methodology are provided in
online materials (Additional file 3).
Results
Measurements of the homocysteine phenotype, the Alu
element methylation phenotype, and the LINE-1 methy-
lation phenotype were available for 760, 628 and 621
participants, respectively. All had genotype data, 533
men had data on all three phenotypes; each analysis
included the maximum number possible. The phenotype
groups had similar frequencies for the MTHFR
rs1801133 TT genotype, but differed by age and hence
differed slightly on age-related variables (Table 1). The
MTHFR rs1801133 TT genotype prevalence in the lar-
gest group, the plasma homocysteine group, was 12.2%,
similar to the frequency reported in a large North
American sample [7].
Age and current smoking status were associated with
homocysteine (P ≤ 0.001), age was associated with Alu
(P ≤ 0.005), and current smoking was associated with
LINE-1 (P = 0.055). Folate, vitamin B-6, and vitamin B-
12 were associated with homocysteine (P ≤ 0.005), vita-
min B-6 was associated with Alu (P ≤ 0.05), and these
biomarkers had little or no association with LINE-1.
Models exploring the SNP–phenotype association were
adjusted for age, smoking, and nutrient residuals.
Adjusting for age and smoking made little difference to
the coefficients for each SNP. The set of SNPs compris-
ing the most significant associations was nearly identical
Table 1 Characteristics of Normative Aging Study participants, 1961-2001, with measurements on three phenotypes.
Plasma
homocysteine
a
Global genomic DNA methylation (Alu
elements)
b
Global genomic DNA methylation (LINE-
1 elements)
b
N = 760 N = 628 N = 621
Age at phenotype measurement 68.6 (7.3)* 72.5 (6.8) 72.5 (6.8)
Education - college graduate or
higher (%)
26.8 28.6 28.7
White (%) 100 100 100
Baseline BMI (kg/m
2) 25.9 (2.9) 25.9 (2.9) 25.9 (2.9)
Cigarette smoking
c
Current (%) 6.7 5.4 5.5
Former (%) 63.0 63.4 63.5
Never (%) 30.3 31.2 31.1
Alcohol intake (% consuming ≥ 2
drinks/day)
12.4 13.7 13.5
Baseline diabetes diagnosis (%) 0.13 0.16 0.16
Baseline systolic blood pressure (mm
Hg)
122.1 (12.7) 121.7 (12.5) 121.6 (12.6)
MTHFR 677 C>T (rs1801133) TT
genotype (%)
12.2 12.3 12.6
Plasma folate (ng/ml)
d 10.4 (5.7) 17.2 (15.1) 17.0 (14.9)
Plasma vitamin B-6 (pmol/ml) 84.9 (85.3) 104.6 (96.1) 104.8 (96.7)
Plasma vitamin B-12 (pg/ml) 458.9 (190.6) 512.8 (371.2) 514.9 (373.8)
Plasma total homocysteine (nmol/
ml)
10.6 (3.7) 11.0 (4.2) 10.9 (4.2)
Global DNA methylation in Alu
elements (%)
26.3 (1.1)
Global DNA methylation in LINE
elements (%)
76.9 (1.9)
*mean (standard deviation) unless otherwise indicated
aN for homocysteine group ranges from 730 to 760 for variables in table.
bMen in the two global genomic methylation groups were very similar, and dates of marker collection were nearly identical. N for Alu group ranges from 618t o
628, and N for LINE-1 group ranges from 611 to 621.
cSmoking status was assessed using most recent data prior to phenotype measurement.
dHomocysteine and corresponding plasma folate, vitamin B-6, and vitamin B-12 data were collected prior to the initiation of folate fortification; global genomic
methylation markers, and corresponding plasma nutrient markers were measured post-folate fortification, in a later time period.
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adjustment for the MTHFR rs1801133 variant made lit-
tle or no difference to the SNP regression coefficients.
The most statistically significant SNPs for each pheno-
type were relatively common (MAF ≥13%), and the set
of most significant SNPs was unique to each phenotype
(Tables 2, 3, and 4 and Figure 1).
Total plasma homocysteine phenotype
Of the 20 SNPs with a nominal P ≤ 0.005, five were also
significant at the FDR threshold (P ≤ 0.05) (Table 2).
These 5 SNPs comprise 3 genes: formiminotransferase
cyclodeaminase (FTCD; 1 SNP, intronic), solute carrier
family 19 (folate transporter), member 1 (SLC19A1,3
SNPs, representing coding nonsynonymous, 5’ region,
and intronic variants), and solute carrier family 19,
member 3 (SLC19A3, 1 SNP, intronic). Genetic variation
in all 5 SNPs was positively associated with plasma
homocysteine levels, and effects were similar in direc-
tion and magnitude (variant genotypes associated with a
4.9-7.2% higher plasma total homocysteine vs. the refer-
ent genotype). In each case, the association of the
genotype with homocysteine was partially mediated by
nutrients; when plasma folate and vitamin B-6 or B-12
biomarkers were added to the models, the regression
coefficients were reduced by 29% for FTCD rs2277820,
by 43% for SLC19A1 rs1051266, rs1131596, and
rs4819130, and by 34% for SLC19A3 rs13007334 (data
not shown). A model containing a nonredundant set of
3o ft h et o p5F D R - s i g n i f i c a n tS N P s( FTCD rs2277820,
SLC19A3 rs13007334, SLC19A1 rs1051266) explained
3.6% of the variation in plasma homocysteine beyond
that explained by age, smoking, and folate, B-6, and B-
12 residuals (data not shown); the set of 3 SNPs was sta-
tistically significant (LRT = 17.6, P = 0.0005, 3 degrees
of freedom, df), and the coefficients for each SNP were
similar to coefficients from single SNP models. Consid-
ering the MTHFR genotype in more detail, the TT geno-
type group (vs. CC) had elevated homocysteine (nominal
P = 0.0052), but the CT genotype had no association
with homocysteine (nominal P = 0.8107); thus, the
MTHFR genotype did not pass preset FDR thresholds.
In models investigating interactions between each SNP
and MTHFR rs1801133, 4 interaction terms were below
Table 2 The most statistically significant associations (P ≤ 0.005) between single nucleotide polymorphisms and the
plasma homocysteine phenotype
a, e
Gene Name rs# Nominal P Effect
c Chr. Coded allele Coded allele frequency Genetic Model
g SNP Type
h
FTCD rs2277820 3.09E-04
b 7.22% 21 T 26% O I
SLC19A1 rs1051266 4.16E-04
b 5.04% 21 A 44% A CN
SLC19A1 rs1131596 4.31E-04
b 5.03% 21 C 44% A 5’
SLC19A3 rs13007334 4.61E-04
b 6.89% 2 C 46% O I
SLC19A1 rs4819130 5.65E-04
b 4.94% 21 C 44% A I
MTHFD1L rs11754661
d 1.51E-03 49.98% 6 A 7% R I
DNMT1 rs2228611 2.42E-03 -6.44% 19 G 49% D CS
ALDH1L1 rs3772424 2.52E-03 6.14% 3 A 20% D I
GGH rs4617146 2.55E-03 5.31% 8 T 19% A I
CELF1 rs4752843 2.74E-03 -5.72% 11 C 14% A I
SLC19A1 rs12482346 3.02E-03 4.08% 21 T 44% A I
SLC19A1 rs2297291 3.39E-03 6.07% 21 A 41% D I
TCN2 rs4820886 3.41E-03 -17.30% 22 G 13% R I
TCN2 rs9621049 3.41E-03 -17.30% 22 T 13% R CN
GLDC rs7848919 3.52E-03 5.70% 9 G 32% D 3’
SARDH rs2502741
f 3.60E-03 6.60% 9 A 50% D I
SLC19A1 rs1051298 3.68E-03 3.98% 21 T 44% A 3’
CBS rs6586282 4.06E-03 -5.80% 21 T 18% O I
FOLH1 rs202673 4.08E-03 -19.30% 11 G 14% R I
MTHFD1 rs1950902
f 4.19E-03 -5.18% 14 T 16% A CN
aModel adjusted for age, smoking, and residuals of plasma folate, plasma vitamin B-6, and plasma vitamin B-12; forward strand allele shown.
bFDR-adjusted P values reached False Discovery Rate significance threshold of 0.05.
cEffect is shown as percent change in plasma homocysteine levels.
dSparse data (fewer than 5 individuals per category) for some genotype categories.
eNo SNPs map to more than one gene.
fLower quality SNP.
gD:Dominant; R:Recessive; A:Additive; O:Overdominant.
h5’:5’ region; 3’:3’ region; CN:Coding nonsynonymous; CS:Coding synonymous; I:Intronic.
Wernimont et al. BMC Medical Genetics 2011, 12:150
http://www.biomedcentral.com/1471-2350/12/150
Page 4 of 10the FDR threshold (FDR-adjusted P value ≤ 0.2) for the
homocysteine phenotype (Additional file 4). No SNP–
nutrient (folate, B-6, or B-12) interaction coefficients
reached FDR-significance (FDR-adjusted P value ≤ 0.2;
Additional file 5). The MTHFR–folate interaction did
not reach preset statistical thresholds (pnominal = 0.0578),
but the pattern of interaction supported a greater asso-
ciation of MTHFR TT genotype with homocysteine con-
ditional on lower folate status.
Global genomic DNA methylation phenotype: Alu
elements
In analyses of the Alu element methylation phenotype, 8
SNPs were statistically significant with a nominal P ≤
0.005; however, none were statistically significant at the
FDR threshold (FDR-adjusted P value ≤ 0.05) (Table 3).
There was little or no mediation of the association by
nutrients or plasma homocysteine levels (data not
shown). There were no SNP–nutrient interactions with
folate or B-12 that reached FDR thresholds for statistical
significance (FDR-adjusted P ≤ 0.2) (Additional file 6).
Three SNPs had an FDR-significant interaction with
plasma vitamin B-6 (Additional file 6); these interactions
involved 3 intronic SNPs in 2 genes, aminomethyltrans-
ferase (AMT, rs1464567 and rs1464566) and DNA (cyto-
sine-5-)-methyltransferase 3 beta (DNMT3B, rs1883729).
Comparing men with the AMT rs1464567 CC/CG geno-
type to the GG genotype, the mean Alu element methy-
lation was 0.4 SD higher at low B-6, 0.1 SD higher at
median B-6, and 0.4 SD lower at high B-6. Comparing
men with the AMT rs1464566 GG/GA genotype to the
AA genotype, the mean Alu element methylation was
0.4 SD higher at low B-6, 0.1 SD higher at median B-6,
and 0.3 SD lower at high B-6. Comparing men with the
DNMT3B rs1883729 AA genotype to the AG/GG geno-
type, the mean Alu element methylation was 0.1 SD
lower at low B-6, 0.3 SD higher at median B-6, and 0.8
SD higher at high B-6.
Global genomic DNA methylation phenotype: LINE-1
elements
No SNP main effect associations reached the FDR-sig-
nificance threshold for LINE-1 methylation (FDR-
adjusted P ≤ 0.05; Table 4). There were no SNP–
Table 3 The most statistically significant associations (P ≤ 0.005) between single nucleotide polymorphisms and the
Alu methylation phenotype a, b, d, f
Gene rs# Nominal P Effect
c Chr Coded allele Coded allele frequency Genetic Model
g Type
h
GNMT rs1051218
e 2.14E-04 -0.57 6 T 3% D 3’
DNMT3B rs2424914 2.16E-03 0.30 20 G 45% R I
SLC25A32 rs3134297
e 2.20E-03 0.65 8 C 20% R 5’
DNMT3B rs2424922 2.21E-03 0.30 20 C 45% R CS
DNMT3B rs6058891 2.21E-03 0.30 20 C 45% R CS
MTHFD1L rs1738574 2.39E-03 0.24 6 T 45% O I
AHCYL2 rs1665105 3.87E-03 0.16 7 T 44% A 3’
SARDH rs129886 3.92E-03 -0.60 9 T 19% R 3’
aModel adjusted for age, smoking, and residuals of plasma folate, plasma vitamin B-6, and plasma vitamin B-12; forward strand allele shown;
bNo FDR-adjusted P values reached False Discovery Rate significance threshold of 0.05.
cEffect represents per genotype change in Alu element methylation standard deviation.
dNo sparse data (fewer than 5 individuals per category) for any genotype categories of these SNPs.
eSNP maps to more than one gene (rs1051218 also maps to PEX6, rs3134297 also maps to WDSOF1/DCAF13).
fNo lower quality SNPs.
gD:Dominant; R:Recessive; A:Additive; O:Overdominant.
h5’:5’ region; 3’:3’ region; CN:Coding nonsynonymous; CS:Coding synonymous; I:Intronic.
Table 4 The most statistically significant association (P ≤ 0.005) between single nucleotide polymorphisms and the
LINE-1 methylation phenotype
a, b, d, e, f
Gene rs# Nominal P Effect
c Chr Coded allele Coded allele frequency Genetic Model
g Type
h
MTHFR rs12121543 4.29E-03 0.48 1 A 24% R I
aModel adjusted for age, smoking, and residuals of plasma folate, plasma vitamin B-6, and plasma vitamin B-12; forward strand allele shown.
bNo FDR-adjusted P values reached False Discovery Rate significance threshold of 0.05.
cEffect represents per genotype change in LINE-1 element methylation standard deviation.
dNo sparse data (fewer than 5 individuals per category) for any genotype categories of these SNPs.
eNo SNPs map to more than one gene.
fNo lower quality SNPs.
gD:Dominant; R:Recessive; A:Additive; O:Overdominant.
h5’:5’ region; 3’:3’ region; CN:Coding nonsynonymous; CS:Coding synonymous; I:Intronic.
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FDR-significance levels (FDR-adjusted P ≤ 0.2) (Addi-
tional file 7). An interaction of plasma B-6 with 1 SNP
was significant at the FDR threshold of P ≤ 0.2
(rs17080689, an intronic SNP in methylenetetrahydrofo-
late dehydrogenase (NADP+ dependent) 1-like,
MTHFD1L) (Additional file 7), suggesting that the rela-
tion of the SNP to LINE-1 methylation varied according
to plasma levels of vitamin B-6. Comparing participants
with the MTHFD1L rs17080689 CA genotype to the
CC/AA genotype, mean LINE-1 element methylation
was 0.6 SD higher at low B-6, 0.2 SD higher at median
B-6, and 0.4 SD lower at high B-6.
Discussion
We investigated sequence variation in a network of can-
didate genes involved in one-carbon metabolism in rela-
tion to plasma total homocysteine and two measures of
global genomic DNA methylation (Alu, LINE-1).
Genes involved in absorption and transport had the
most statistically significant associations with the homo-
cysteine phenotype; about 30-40% of the association was
mediated through plasma folate and vitamin B-6 and B-
12 levels. For the Alu-element methylation phenotype,
the top hits were in genes involved in mitochondrial
metabolism, nuclear metabolism, and methylation/
homocysteine metabolism. For the LINE-1 methylation
phenotype, the top SNP was in a gene in the methyla-
tion/homocysteine pathway. There was no evidence that
nutrient biomarkers mediated the association of SNPs
with the methylation phenotypes.
The set of genes represented in the top hits was
unique to each phenotype, although pleiotropy was
identified for plasma homocysteine and Alu element
methylation involving the MTHFD1L and sarcosine
dehydrogenase (SARDH) genes.
Plasma total homocysteine phenotype
SLC19A1. There were FDR-significant associations
between 3 SNPs in the SLC19A1 gene and plasma total
homocysteine; the direction and magnitude of associa-
tion were similar. Thus, each copy of the coding nonsy-
nonymous rs1051266 A allele, the 5’region rs1131596 C
allele, and the intronic rs4819130 C allele was associated
with about a 5.0% increase in plasma homocysteine.
HapMap plots indicate high LD across the SLC19A1
gene, thus the three SNPs may represent a single effect.
The SLC19A1 gene encodes a transporter involved in
folate and thiamine uptake and may play a role in intra-
cellular folate distribution [21]. Transporter expression
may be regulated by folate status [21]. About half of the
association of these three SLC19A1 SNPs with homocys-
teine was mediated by plasma folate and vitamins B-6/
B-12. The nonsynonymous SLC19A1 rs1051266 SNP
was previously associated with blood folate levels
[22,23], and risk of intracranial aneurysm [24], but not
with homocysteine [23,25] or abdominal aortic aneur-
ysm [25]. The 5’ region SLC19A1 rs1131596 SNP was
associated with reduced RBC folate levels in coronary
artery disease patients and decreased SLC19A1 protein
expression [26,27]. Genetic variation in SLC19A1 may
influence homocysteine levels, mediated by changes in
nutrient biomarkers.
FTCD.T h ei n t r o n i cFTCD rs2277820 SNP was asso-
ciated with plasma total homocysteine. The CT geno-
type group was 7.2% higher on plasma total
homocysteine vs. the CC/TT group. FTCD encodes a
Golgi-associated enzyme involved in the production of
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Ȃ

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Figure 1 Manhattan plot. Folate-related SNPs as predictors of plasma total homocysteine and global genomic DNA methylation phenotypes.
Models adjusted for age, smoking status, and folate, vitamin B-6, and vitamin B-12 residuals. Horizontal lines represent nominal P values of 0.05
(lower dashed line), 0.02 (center solid line) and 0.005 (upper dashed line). Boxes indicate SNPs that reached False Discovery Rate significance.
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Page 6 of 105,10-methenyl-tetrahydrofolate (THF) [1]. Based on
HapMap LD patterns the association with the intronic
rs2277820 SNP may proxy variation elsewhere in the
gene. Mutations in FTCD are associated with inherited
disorders of folate metabolism [28]. 29% of the associa-
tion between rs2277820 and homocysteine was mediated
through plasma folate and vitamins B-6/B-12.
SLC19A3. An FDR-significant association was identi-
fied between the intronic rs13007334 SNP in SLC19A3
and plasma total homocysteine. The CT genotype group
was 6.9% higher on plasma total homocysteine vs. the
CC/TT group. The SLC19A3 gene belongs to the folate
transporter family and encodes a thiamine transporter
[21]. Although SLC19A3 is not known to transport
folate or vitamins B-6/B-12, 34% of the SNP–homocys-
teine association was mediated by these nutrients. No
prior reports link SLC19A3 to biochemical or disease
phenotypes, and a biological basis for the link to thia-
mine metabolism could not be identified.
The variability in homocysteine explained by the
model containing the set of the 3 most significant non-
redundant SNP hits was 3.6%, a small proportion of the
estimated > 50% heritability in homocysteine [29,30],
and similar to the proportion explained by age and
smoking together.
There were four FDR-significant interactions between
studied SNPs and MTHFR rs1801133 (Additional file 4);
the most statistically significant was for the ALDH1L1
rs2305230 SNP. In participants with the ALDH1L1
rs2305230 AA genotype, men with 1 copy of the
MTHFR rs1801133 T allele had plasma homocysteine
64% higher than men with no copies. However, among
participants with the ALDH1L1 rs2305230 AC/CC geno-
type, men with 1 copy of the MTHFR rs1801133 T allele
had plasma homocysteine 2.1% lower than men with no
copies.
There were no FDR-significant interactions between
studied SNPs and plasma folate, vitamin B-6, or vitamin
B-12 for the plasma homocysteine phenotype. The null
results may be due to an overly conservative FDR signif-
icance threshold, network compensation for genetic and
nutritional stresses, or inadequate power to evaluate
interactions involving low MAF SNPs; also, the folate
status for men in the NAS was relatively high in com-
parison to national averages as reported in Pfeiffer et al
[31], and SNP–nutrient interactions may be attenuated
in this range of folate status. The MTHFR rs1801133
SNP, which is expected to interact with folate in pre-
dicting the homocysteine phenotype, had a nonsignifi-
cant interaction in these data (nominal Pinteraction =
0.0578), but the association of MTHFR with homocys-
teine was stronger at lower concentrations of plasma
folate (data not shown).
Ac l u s t e ro fS N P –vitamin B-6 interactions was noted
for variants in the CBS gene, but the P values for these
interaction terms were about 0.1 and did not reach
thresholds set prior to the analysis. These findings sug-
gest that interactions between vitamin B-6 and genetic
variants in the SHMT1 and CBS genes may only be evi-
dent with very low vitamin B-6 status, which is consis-
tent with previous work [32,33]. A systematic review of
literature published prior to August, 2009 revealed only
one report of a statistically significant interaction
between genetic variation in SHMT1 (rs1979277) and B-
6 [34].
Global genomic DNA methylation phenotype (Alu
elements)
There were no FDR-significant main effect associations
for the Alu element methylation outcome. None of the
SNP–folate or SNP–vitamin B-12 interaction terms
reached FDR significance thresholds. Given that the Alu
phenotype was measured after the introduction of man-
datory folate fortification in the U.S., findings may be
limited. Three FDR-significant SNP–vitamin B-6 inter-
actions were identified, including two intronic SNPs in
the AMT gene (rs1464567 and rs1464566) and one
intronic SNP in the DNMT3B gene (rs1883729). The
AMT gene encodes an enzyme that functions in the
vitamin B-6-dependent mitochondrial glycine cleavage
system [35]. B-6 interactions involving SNPs in GLDC
were among the top nominally significant hits for the
homocysteine and Alu methylation phenotypes, but did
not reach FDR-significance. The DNMT3B gene encodes
a DNA methyltransferase enzyme that is localized to the
nucleus, developmentally regulated, and functions to
establish de novo methylation patterns [36,37];
DNMT3B expression is associated with cancer [36-38].
Although cell culture studies have not supported Alu
elements as DNMT3B targets [36,39] in both in vitro
and in vivo models, DNMT3b protein levels were down-
regulated by B vitamin deficiency (deficiency of folate,
B-6, and B-12 together), de novo methylation was sup-
pressed both in vitro and in vivo under conditions of B
vitamin deficiency[40], and S-adenosylmethionine levels
were markedly decreased in response to lowered B-6
concentrations in culture medium [32] consistent with
the direction of association observed here.
Global genomic DNA methylation phenotype (LINE-1
elements)
There were no FDR-significant associations observed for
the LINE-1 methylation phenotype. There were no
FDR-significant interactions between SNPs and folate or
vitamin B-12; the measurement of LINE-1 in Normative
Aging Study men took place after the introduction of
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variation may have limited findings. A single SNP–vita-
min B-6 interaction was significant at the FDR threshold
for the intronic rs17080689 in the MTHFD1L gene. The
MTHFD1L gene product functions downstream from
the vitamin B-6-dependent glycine cleavage system [41]
and intronic variation in MTHFD1L was previously
associated with CVD [42].
Conclusions
Strengths of the present study include investigation of a
large cohort with homocysteine data collected prior to
the introduction of mandatory folate-fortification in the
U.S. Also, SNP selection for the genotyping assay
reflected functional, LD, and physical coverage of genes.
Using a systematic approach, we identified the best
genetic models for each SNP, then tested single SNPs,
the interaction of each SNP with MTHFR rs1801133,
and the interaction of each SNP with folate, vitamin B-6
and vitamin B-12. Findings were corrected for multiple
comparisons and those surpassing the FDR threshold
were discussed in more detail. Weaknesses of the study
include the fact that methylation (but not homocysteine)
measures were collected after the introduction of man-
datory folate fortification in the U.S., which may have
limited variation in B-vitamin status. Information on
additional nutrients such as choline would have allowed
a more complete evaluation of gene-nutrient interac-
tions. S-adenosylhomocysteine and/or the ratio of S-ade-
nosylmethionine to S-adenosylhomocysteine are likely to
be more sensitive indicators of vascular disease risk than
homocysteine [43,44], but were not measured. The
methylation phenotypes studied here are believed to be
an adequate proxy of genome-wide DNA methylation.
Gene-specific methylation data was not available;
furthermore, because the folate-mediated one-carbon
network functions to generate cellular methylation
potential and thus contributes to numerous methylation
reactions, it may be more appropriate to evaluate folate
network genetic variation in relation to global measures
of methylation. Finally, due to genotyping failure, some
key variants could not be analyzed, for example
rs6922269 in MTHFD1L [42], although proxies were
selected purposefully to address this limitation.
The most significant hits for the homocysteine and
methylation outcomes reflected genes involved in the
generation of one-carbon units, including SLC19A1 and
FTCD. Because a unique set of genes was identified for
each phenotype, and because the top hits could not be
predicted on the basis of hypothesized impact on cellu-
lar methylation potential, this work suggests that not all
folate effects are mediated through the ratio of S-adeno-
sylmethionine to S-adenosylhomocysteine. Thus, beyond
the well-described MTHFR rs1801133 SNP,
polymorphisms in other genes make important contri-
butions to homocysteine and global genomic DNA
methylation phenotypes. Furthermore, some associations
are sensitive to nutritional status of B vitamins. Future
work should continue to include a broad evaluation of
one-carbon network genetic and nutritional variation in
unfortified or pre-fortification populations and extend
these findings for CVD biomarkers to an investigation
of CVD phenotypes.
Additional material
Additional file 1: 52 genes in the folate-mediated one-carbon
pathway.
Additional file 2: 330 folate-related SNPs assayed in men in the
Normative Aging Study.
Additional file 3: Supplemental methods.
Additional file 4: Epistatic interactions with the MTHFR rs1801133
SNP and plasma homocysteine. The most statistically significant
associations (FDR-adjusted Likelihood Ratio Test P ≤ 0.2) for SNP by
MTHFR rs1801133 interactions in relation to the plasma homocysteine
phenotype for men in the Normative Aging Study.
Additional file 5: Gene-nutrient interactions and plasma
homocysteine. The most statistically significant associations (P ≤ 0.02)
for SNP by nutrient interactions in relation to the plasma homocysteine
phenotype for men in the Normative Aging Study.
Additional file 6: Gene-nutrient interactions and Alu element
methylation. The most statistically significant associations (P ≤ 0.02) for
SNP by nutrient interactions in relation to the global genomic DNA
methylation phenotype (Alu elements) for men in the Normative Aging
Study.
Additional file 7: Gene-nutrient interactions and LINE-1 element
methylation. The most statistically significant associations (P ≤ 0.02) for
SNP by nutrient interactions in relation to the global genomic DNA
methylation phenotype (LINE-1 elements) for men in the Normative
Aging Study
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